<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Buprenorphine and naloxone: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Buprenorphine and naloxone: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Buprenorphine and naloxone: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8788" href="/d/html/8788.html" rel="external">see "Buprenorphine and naloxone: Drug information"</a> and <a class="drug drug_patient" data-topicid="11501" href="/d/html/11501.html" rel="external">see "Buprenorphine and naloxone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F52999432"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">FDA Requiring Updates to Opioid Prescribing Information</span>
<span class="collapsible-date">April 2023</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">The FDA has issued a drug safety communication to announce safety-related updates to the prescribing information for immediate-release (IR) and extended-release (ER)/long-acting (LA) opioid analgesics, including updates to Boxed Warnings, Indications and Usage, Dosage and Administration, Warnings and Precautions, and the Medication Guide. These safety labeling changes are intended to provide clarity on appropriate patient populations for opioid treatment, appropriate dosage and administration, and updated information on the risks associated with opioid use. The required safety labeling changes include stating:</p>
<ul>
<li>
<p style="text-indent:0em;">the risk of overdose increases as the dosage increases for all opioid pain medicines;</p></li>
<li>
<p style="text-indent:0em;">IR opioids should not be used for an extended period of time unless a patient's pain remains severe enough to require them and alternative treatment options continue to be inadequate;</p></li>
<li>
<p style="text-indent:0em;">many acute pain conditions treated in the outpatient setting require no more than a few days of an opioid pain medicine;</p></li>
<li>
<p style="text-indent:0em;">it is recommended to reserve ER/LA opioid pain medicines for severe and persistent pain that requires an extended treatment period with a daily opioid pain medicine and for which alternative treatment options are inadequate; and</p></li>
<li>
<p style="text-indent:0em;">a warning about opioid-induced hyperalgesia (OIH), including information on differentiating OIH symptoms from those of opioid tolerance and withdrawal.</p></li></ul>
<p style="text-indent:0em;">Further information may be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use&amp;token=W5X7myh%2Fi%2FQGr76L%2FoSZbu%2BwYKvRHJDB8O4e79tNg%2FJelrlNqz4gv2DJCwSZVkI3gE10g96a4t1z3Z59rSO%2Fb6izsjmacse6U4o7Ho29jYziQVHf0MYzW7j8%2B8LrQ2%2B4Ru4vvCtWrdS3FrWL%2B0kz4ajIBlnws%2B6VB3AxZWaliq8%3D&amp;TOPIC_ID=12919" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use</a>.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F143145"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Bunavail [DSC];</li>
<li>Suboxone;</li>
<li>Zubsolv</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52911944"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>PMS-Buprenorphine-Naloxone;</li>
<li>Suboxone;</li>
<li>TEVA-Buprenorphine/Naloxone</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1051406"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Analgesic, Opioid</span>;</li>
<li>
<span class="list-set-name">Opioid Partial Agonist</span></li></ul></div>
<div class="block dop drugH1Div" id="F143152"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Not all sublingual dosage forms are bioequivalent; when switching between formulations, utilize equivalent doses; the following formulations are considered equivalent: buprenorphine 8 mg sublingual tablet = buprenorphine 8 mg/naloxone 2 mg sublingual film = buprenorphine 5.7 mg/naloxone 1.4 mg sublingual tablet (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511106','lexi-content-ref-SAMSHA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511106','lexi-content-ref-SAMSHA.2'])">Ref</a></span>); see "Switching Between Dosage Forms."</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="702f7cf8-851c-4aec-bbb4-de4c200d09a4">Opioid use disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Opioid use disorder: Note:</b> Do not start induction with buprenorphine until objective and clear signs of withdrawal are apparent (otherwise withdrawal may be precipitated). Withdrawal usually occurs 8 to 12 hours after last short-acting agonist (eg, heroin, oxycodone) and up to 24 to 72 hours after last long-acting agonist (eg, methadone). Psychosocial treatment is recommended in combination with pharmacotherapy in adolescent patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511106'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Sublingual tablets or film: Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Dosing is presented as buprenorphine and is based on the buprenorphine:naloxone 4:1 products (eg, Suboxone); see "Switching Between Dosage Forms" below or manufacturer's labeling for details.</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: Sublingual: Initial: Buprenorphine: 2 to 4 mg; if no signs of precipitated withdrawal after 60 to 90 minutes, may increase buprenorphine in increments of 2 to 8 mg. Once initial dose is tolerated, may increase to a dose that is clinically effective and provides 24 hours of stabilization. Usual maintenance dose range: 4 to 24 mg buprenorphine/day. Doses ≥16 mg/day have been associated with greater efficacy; however, doses &gt;24 mg/day have not been shown to be more effective and may increase risk of diversion. Continue effective maintenance dose for as long as necessary for opioid use disorder; there are no recommended limits on duration of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511106','lexi-content-ref-SAMSHA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511106','lexi-content-ref-SAMSHA.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Switching between dosage forms:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511106','lexi-content-ref-SAMSHA.2','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511106','lexi-content-ref-SAMSHA.2','lexi-content-ref-Manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Switching between sublingual tablets and sublingual film:</i> The same equivalent dosage should be used as the previous administered product with close patient monitoring. <b>Note:</b> There is potential for greater bioavailability with certain sublingual film strengths compared to the same strength of the sublingual tablet; monitor closely for either over- or underdosing when switching patients from one formulation to another.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Switching between sublingual and buccal sites of administration (Suboxone film):</i>
<b></b>Systemic exposure between buccal and sublingual administration of buprenorphine/naloxone sublingual film is similar. Once induction is complete, patients can switch between buccal and sublingual administration without significant risk of under or overdosing.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Switching between sublingual film strengths:</i> Systemic exposure may be different with various combinations of sublingual film strengths; pharmacists should not substitute one or more film strengths for another (eg, switching from three buprenorphine 4 mg/naloxone 1 mg films to a single buprenorphine 12 mg/naloxone 3 mg film, or vice-versa) without health care provider approval, and patients should be monitored closely for either over- or underdosing when switching between film strengths.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Switching between sublingual tablet products:</b> Due to differences in the bioavailability of Zubsolv sublingual tablets compared to other buprenorphine/naloxone sublingual tablets, different strengths must be given to achieve equivalent doses. When switching between Zubsolv and other sublingual tablets, corresponding dosage strengths are as follows:</p>
<p style="text-indent:-2em;margin-left:8em;">Zubsolv buprenorphine 1.4 mg/naloxone 0.36 mg sublingual tablets = buprenorphine 2 mg/naloxone 0.5 mg sublingual tablets.</p>
<p style="text-indent:-2em;margin-left:8em;">Zubsolv buprenorphine 2.9 mg/naloxone 0.71 mg sublingual tablets = buprenorphine 4 mg/naloxone 1 mg sublingual tablets (as two buprenorphine 2 mg/naloxone 0.5 mg sublingual tablets).</p>
<p style="text-indent:-2em;margin-left:8em;">Zubsolv buprenorphine 5.7 mg/naloxone 1.4 mg sublingual tablets = buprenorphine 8 mg/naloxone 2 mg sublingual tablets.</p>
<p style="text-indent:-2em;margin-left:8em;">Zubsolv buprenorphine 8.6 mg/naloxone 2.1 mg sublingual tablets = buprenorphine 12 mg/naloxone 3 mg sublingual tablets (as one buprenorphine 8 mg/naloxone 2 mg sublingual tablet and two buprenorphine 2 mg/naloxone 0.5 mg sublingual tablets).</p>
<p style="text-indent:-2em;margin-left:8em;">Zubsolv buprenorphine 11.4 mg/naloxone 2.9 mg sublingual tablets = buprenorphine 16 mg/naloxone 4 mg sublingual tablets (as two buprenorphine 8 mg/naloxone 2 mg sublingual tablets).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Discontinuation of therapy:</b> When discontinuing buprenorphine/naloxone for long-term treatment of opioid use disorder, gradually decrease the dose over several months to prevent withdrawal; do not abruptly discontinue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511106','lexi-content-ref-SAMSHA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511106','lexi-content-ref-SAMSHA.2'])">Ref</a></span>). A standard tapering approach does not exist; taper should be individualized based on patient response.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51084000"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51084001"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment: No dosage adjustment necessary; use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511106','lexi-content-ref-SAMSHA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511106','lexi-content-ref-SAMSHA.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate impairment: Use for induction is not recommended due to risk of precipitating withdrawal. Use with caution during maintenance treatment (due to reduced clearance of buprenorphine and naloxone, use may not be appropriate) in patients inducted with buprenorphine monotherapy; monitor for buprenorphine toxicity or overdose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-SAMSHA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-SAMSHA.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511106','lexi-content-ref-SAMSHA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511106','lexi-content-ref-SAMSHA.2'])">Ref</a></span>).</p></div>
<div class="block doa drugH1Div" id="F143147"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8788" href="/d/html/8788.html" rel="external">see "Buprenorphine and naloxone: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="702f7cf8-851c-4aec-bbb4-de4c200d09a4">Opioid use disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Opioid use disorder: Note: </b> Prior to induction, consider type of opioid use (ie, long- or short-acting opioid) and time since last use of opioid.</p>
<p style="text-indent:-2em;margin-left:4em;">Patients on heroin or short-acting prescription opioids should initiate buprenorphine/naloxone when signs of opioid withdrawal occur, but no sooner than 12 hours after the last opioid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511106','lexi-content-ref-SAMSHA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511106','lexi-content-ref-SAMSHA.2'])">Ref</a></span>). See dosing section below on "Switching therapies" for guidance on transitioning from methadone to buprenorphine.</p>
<p style="text-indent:-2em;margin-left:4em;">Despite the manufacturer's recommendation to use buprenorphine instead of buprenorphine/naloxone during the induction period for long-acting opioid dependence due to the risk of withdrawal caused by naloxone, some experts recommend the combination product or buprenorphine for induction for long- and short-acting opioids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-SAMSHA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-SAMSHA.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>US labeling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i> Induction:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Titrate induction dose carefully to control acute withdrawal symptoms while avoiding sedation and monitoring for onset of precipitated withdrawal symptoms. Consider lower initial doses in patients with a history of opioid use disorder with a high risk of relapse but not currently dependent on opioids; titration in these patients should occur much more slowly than tolerant patients to avoid oversedation/overdose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-SAMSHA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-SAMSHA.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Buccal film (Bunavail: Buprenorphine 2.1 mg/naloxone 0.3 mg; buprenorphine 4.2 mg/naloxone 0.7 mg; buprenorphine 6.3 mg/naloxone 1 mg): </b>
<b>Note:</b> Bunavail (buccal film) has been discontinued in the United States for &gt;1 year.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Day 1 induction dose:</i> Initial: Buccal: Buprenorphine 2.1 mg/naloxone 0.3 mg; consider an initial dose of buprenorphine ~1 mg and naloxone 0.15 mg in patients with a history of opioid use disorder with a high risk of relapse but not currently dependent on opioids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-SAMSHA.2','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-SAMSHA.2','lexi-content-ref-Manu.1'])">Ref</a></span>). May repeat dose after ~2 hours, based on control of acute withdrawal symptoms; maximum total dose: buprenorphine 4.2 mg/naloxone 0.7 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Day 2 induction dose</i>: Up to buprenorphine 8.4 mg/naloxone 1.4 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Sublingual film (Suboxone: Buprenorphine 2 mg/naloxone 0.5 mg; <b>buprenorphine 4 mg/naloxone 1 mg; buprenorphine 8 mg/naloxone 2 mg; buprenorphine 12 mg/naloxone 3 mg):</b></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Day 1 induction dose:</i> Initial: Sublingual: Buprenorphine 2 mg/naloxone 0.5 mg or buprenorphine 4 mg/naloxone 1 mg; consider an initial dose of buprenorphine 1 mg and naloxone 0.25 mg in patients with a history of opioid use disorder with a high risk of relapse but not currently dependent on opioids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-SAMSHA.2','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-SAMSHA.2','lexi-content-ref-Manu.1'])">Ref</a></span>). May titrate dose, based on control of acute withdrawal symptoms, in buprenorphine 2 mg/naloxone 0.5 mg or buprenorphine 4 mg/naloxone 1 mg increments approximately every 2 hours up to a total dose of buprenorphine 8 mg/naloxone 2 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Day 2 induction dose:</i> Sublingual: Up to buprenorphine 16 mg/naloxone 4 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Sublingual tablet (Zubsolv: Buprenorphine 0.7 mg/naloxone 0.18 mg, buprenorphine 1.4 mg/naloxone 0.36 mg, buprenorphine 2.9 mg/naloxone 0.71 mg, buprenorphine 5.7 mg/naloxone 1.4 mg, buprenorphine 8.6 mg/naloxone 2.1 mg, or buprenorphine 11.4 mg/naloxone 2.9 mg):</b></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Day 1 induction dose:</i> Sublingual: Start with an initial dose of buprenorphine 1.4 mg/naloxone 0.36 mg; based on control of acute withdrawal symptoms, may administer additional doses in increments of 1 to 2 buprenorphine 1.4 mg/naloxone 0.36 mg tablets every 1.5 to 2 hours to a total day 1 dose up to buprenorphine 5.7 mg/naloxone 1.4 mg. Some patients (eg, those with recent exposure to buprenorphine) may tolerate up to buprenorphine 4.2 mg/naloxone 1.08 mg as a single, second dose.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Day 2 induction dose:</i> Sublingual: Up to buprenorphine 11.4 mg/naloxone 2.9 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance:</i>
<b>Note: </b>In patients with pain, temporarily increasing the dose by 20% to 25% or dosing frequency (eg, divide total daily dose over 3 to 4 times per day) may maximize the analgesic properties for pain management (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511106'])">Ref</a></span>). Buprenorphine may be safely dosed 2 or 3 times a week instead of once daily when more convenient dosing schedules are needed; divide the total weekly dose over 2 or 3 days per week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15664721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15664721'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Buccal film (Bunavail: Buprenorphine 2.1 mg/naloxone 0.3 mg, buprenorphine 4.2 mg/naloxone 0.7 mg, buprenorphine 6.3 mg/naloxone 1 mg):</b>
<b>Note:</b> Bunavail (buccal film) has been discontinued in the United States for &gt;1 year. Buccal: Target dose: Buprenorphine 8.4 mg/naloxone 1.4 mg once daily; dosage should be adjusted in increments/decrements of buprenorphine 2.1 mg/naloxone 0.3 mg to a level that maintains treatment and suppresses opioid withdrawal symptoms; usual range: Buprenorphine 2.1 to 12.6 mg/naloxone 0.3 to 2.1 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Sublingual film (Suboxone: Buprenorphine 2 mg/naloxone 0.5 mg; buprenorphine 4 mg/naloxone 1 mg; buprenorphine 8 mg/naloxone 2 mg; buprenorphine 12 mg/naloxone 3 mg): </b>Sublingual or buccal: Target dose: Buprenorphine 16 mg/naloxone 4 mg once daily; dosage should be adjusted in increments/decrements of buprenorphine 2 mg/naloxone 0.5 mg or buprenorphine 4 mg/naloxone 1 mg to a level that maintains treatment and suppresses opioid withdrawal symptoms; usual range: Buprenorphine 4 to 24 mg/naloxone 1 to 6 mg once daily. Buprenorphine doses ≥16 mg/day have been associated with greater efficacy; limited evidence exists for doses &gt;24 mg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Sublingual tablet (buprenorphine 2 mg/naloxone 0.5 mg or buprenorphine 8 mg/naloxone 2 mg): </b>Sublingual: Target dose: Buprenorphine 16 mg/naloxone 4 mg once daily; dosage should be adjusted in increments/decrements of buprenorphine 2 mg/naloxone 0.5 mg or buprenorphine 4 mg/naloxone 1 mg to a level that maintains treatment and suppresses opioid withdrawal symptoms; usual range: Buprenorphine 4 to 24 mg/naloxone 1 to 6 mg once daily. Buprenorphine doses ≥16 mg/day have been associated with greater efficacy; limited evidence exists for doses &gt;24 mg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Sublingual tablet (Zubsolv: Buprenorphine 0.7 mg/naloxone 0.18 mg, buprenorphine 1.4 mg/naloxone 0.36 mg, buprenorphine 2.9 mg/naloxone 0.71 mg, buprenorphine 5.7 mg/naloxone 1.4 mg, buprenorphine 8.6 mg/naloxone 2.1 mg, or buprenorphine 11.4 mg/naloxone 2.9 mg):</b> Sublingual: Target dose: Buprenorphine 11.4 mg/naloxone 2.9 mg once daily; dosage should be adjusted in increments/decrements of buprenorphine 2.9 mg/naloxone 0.71 mg or lower to a level that maintains treatment and suppresses opioid withdrawal symptoms; usual range: Buprenorphine 2.9 to 17.2 mg/naloxone 0.71 to 4.2 mg once daily. Doses higher than buprenorphine 17.2 mg/naloxone 4.2 mg have not been demonstrated to provide any clinical advantage.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Switching therapies:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Sublingual tablets and sublingual film:</b> Same dosage should be used as the previous administered product. <b>Note:</b> Potential for greater bioavailability with certain sublingual film strengths compared to the same strength of the sublingual tablet; monitor closely for either over- or underdosing when switching patients from one formulation to another.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Buccal film and sublingual tablets or films:</b> Due to differences in the bioavailability of Bunavail buccal films compared to other buprenorphine/naloxone sublingual tablets, different strengths must be given to achieve equivalent doses. When switching between Bunavail and other sublingual tablets, corresponding dosage strengths are as follows:</p>
<p style="text-indent:-2em;margin-left:6em;">Bunavail buprenorphine 2.1 mg/naloxone 0.3 mg = buprenorphine 4 mg/naloxone 1 mg sublingual tablets or films.</p>
<p style="text-indent:-2em;margin-left:6em;">Bunavail buprenorphine 4.2 mg/naloxone 0.7 mg = buprenorphine 8 mg/naloxone 2 mg sublingual tablets or films.</p>
<p style="text-indent:-2em;margin-left:6em;">Bunavail buprenorphine 6.3 mg/naloxone 1 mg = buprenorphine 12 mg/naloxone 3 mg sublingual tablets or films.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Switching between sublingual film strengths:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Systemic exposure may be different with various combinations of sublingual film strengths; pharmacists should not substitute one or more film strengths for another (eg, switching from three buprenorphine 4 mg/naloxone 1 mg films to a single buprenorphine 12 mg/naloxone 3 mg film, or vice-versa) without health care provider approval, and patients should be monitored closely for either over- or underdosing when switching between film strengths.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Switching between sublingual and buccal sites of administration (Suboxone):</b> Systemic exposure between buccal and sublingual administration of buprenorphine/naloxone sublingual film is similar. Once induction is complete, patients can switch between buccal and sublingual administration without significant risk of under or overdosing.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Switching between sublingual tablet products:</b> Due to differences in the bioavailability of Zubsolv sublingual tablets compared to other buprenorphine/naloxone sublingual tablets, different strengths must be given to achieve equivalent doses. When switching between Zubsolv and other sublingual tablets, corresponding dosage strengths are as follows:</p>
<p style="text-indent:-2em;margin-left:6em;">Zubsolv buprenorphine 1.4 mg/naloxone 0.36 mg sublingual tablets = buprenorphine 2 mg/naloxone 0.5 mg sublingual tablets.</p>
<p style="text-indent:-2em;margin-left:6em;">Zubsolv buprenorphine 2.9 mg/naloxone 0.71 mg sublingual tablets = buprenorphine 4 mg/naloxone 1 mg (as two buprenorphine 2 mg/naloxone 0.5 mg sublingual tablets).</p>
<p style="text-indent:-2em;margin-left:6em;">Zubsolv buprenorphine 5.7 mg/naloxone 1.4 mg sublingual tablets = buprenorphine 8 mg/naloxone 2 mg sublingual tablets.</p>
<p style="text-indent:-2em;margin-left:6em;">Zubsolv buprenorphine 8.6 mg/naloxone 2.1 mg sublingual tablet = buprenorphine 12 mg/naloxone 3 mg sublingual tablets (as one buprenorphine 8 mg/naloxone 2 mg sublingual tablets and two buprenorphine 2 mg/naloxone 0.5 mg sublingual tablets).</p>
<p style="text-indent:-2em;margin-left:6em;">Zubsolv buprenorphine 11.4 mg/naloxone 2.9 mg sublingual tablet = buprenorphine 16 mg/naloxone 4 mg sublingual tablets (as two buprenorphine 8 mg/naloxone 2 mg sublingual tablets).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Buprenorphine to naltrexone: </b>Taper the buprenorphine dose gradually and discontinue. Wait 7 to 14 days before initiating treatment with naltrexone. A naloxone challenge may be used to demonstrate an absence of physical dependence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511106'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Buprenorphine to methadone: </b>No time delay is required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511106'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Methadone to buprenorphine</b>
<i>:</i> Taper the methadone dose gradually to 30 to 40 mg per day and remain on that dose for ≥7 days. The patient should be in mild withdrawal before starting buprenorphine; this is typically 24 to 48 hours after the last dose of methadone. Initiating buprenorphine at lower doses (eg, 2 mg) decreases risk of precipitated methadone withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511106','lexi-content-ref-SAMSHA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511106','lexi-content-ref-SAMSHA.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Naltrexone to buprenorphine:</b> Begin buprenorphine ~1 day following last dose of oral naltrexone and ~28 days following last dose of IM naltrexone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511106'])">Ref</a></span>).</p>
<p style="text-indent:0em;">
<b>
<i>Canadian labeling:</i></b> Sublingual tablet: <b>Note:</b> Dose based on buprenorphine content.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Induction: </i>Day 1: Initial: 4 mg as single dose; may repeat dose if necessary depending on patient's requirement; target dose: 8 to 12 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance: </i>Day 2 and beyond: Titrate per response in increments or decrements of 2 to 8 mg; usual maintenance dose: 12 to 16 mg once daily (maximum: 24 mg/day). Upon stabilization, may consider less frequent administration of corresponding equivalent dose (eg, 16 mg every other day instead of 8 mg/day or 3 times/week dosing [eg, Monday-Wednesday-Friday] with twice the maintenance dose on Monday and Wednesday and three times the maintenance dose on Friday); continue to limit maximum dose to 24 mg/day on any single day. <b>Note:</b> When switching dosing to less than once daily, monitor all patients for at least 90 minutes following the initial dose of the new regimen. The less frequent dosing regimen is not recommended in patients dependent on concurrent CNS-active drugs, including ethanol.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed doses: </i>Reassess patients who have missed multiple doses; initial induction doses may be required when resuming therapy.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy: </b>When discontinuing buprenorphine/naloxone for long-term treatment of opioid use disorder, gradually decrease the dose over several months to prevent withdrawal; do not abruptly discontinue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511106','lexi-content-ref-SAMSHA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511106','lexi-content-ref-SAMSHA.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990784"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been adequately studied); use with caution.</p></div>
<div class="block doha drugH1Div" id="F50987966"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment: Use for induction is not recommended due to risk of precipitating withdrawal. Use with caution during maintenance treatment (due to reduced clearance of buprenorphine and naloxone, use may not be appropriate) in patients inducted with buprenorphine monotherapy; monitor for buprenorphine toxicity or overdose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-SAMSHA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-SAMSHA.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-SAMSHA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-SAMSHA.2'])">Ref</a></span>).</p></div>
<div class="block arsc drugH1Div" id="F57077927"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Dental effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cases of tooth decay, <b>dental caries</b> (cavities), oral infections, and <b>tooth loss</b> have been reported with the use of transmucosal (eg, buccal, sublingual) buprenorphine-containing products in patients with and without a history of dental disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mechanism:</i> Non–dose-related; idiosyncratic; mechanism not clearly established. May be related to prolonged tooth exposure to the acidic medication formulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36511932','lexi-content-ref-24511440']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36511932','lexi-content-ref-24511440'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Onset:</i> Delayed; identification of dental problems occurred a mean of 45.7 months (range: 5 to 77 months) after initiation of buprenorphine-containing transmucosal therapy in one case series (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24511440']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24511440'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Opioid-induced constipation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Opioid-induced <b>constipation</b> (OIC) is the most common subtype of opioid-induced bowel dysfunction, which is a broader term that encompasses additional GI opioid-induced adverse reactions including <b>nausea</b>, vomiting, and gastroesophageal reflux. Symptoms of OIC may include decreased frequency of bowel movements, straining to pass bowel movements, a sense of incomplete evacuation, and/or hard stools (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30340754','lexi-content-ref-30788113','lexi-content-ref-30778756']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30340754','lexi-content-ref-30788113','lexi-content-ref-30778756'])">Ref</a></span>). Tolerance does not develop to OIC, and symptoms are reversible after discontinuation of the opioid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28034973','lexi-content-ref-11755892','lexi-content-ref-30778756']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28034973','lexi-content-ref-11755892','lexi-content-ref-30778756'])">Ref</a></span>). Buprenorphine, as a partial mu agonist, is associated with a lower incidence of OIC than morphine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21718572','lexi-content-ref-16010532']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21718572','lexi-content-ref-16010532'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Time-related; mu-opioid receptor stimulation in the GI tract results in delayed gastric emptying, decreased peristalsis, decreased water and chloride secretion into the intestinal lumen, and slowed bowel motility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30788113','lexi-content-ref-15153834','lexi-content-ref-11755892']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30788113','lexi-content-ref-15153834','lexi-content-ref-11755892'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; changes in peristalsis may occur 5 to 25 minutes after administration of opioids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15153834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15153834'])">Ref</a></span>). However, OIC is defined based on a 7-day period of change (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30778756']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30778756'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other medications that cause constipation (eg, anticholinergic medications) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29671504']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29671504'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Opioid-induced respiratory depression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious, life-threatening, or fatal opioid-induced respiratory depression (OIRD) may occur with use of buprenorphine, especially during dose escalation or with misuse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16547090','lexi-content-ref-20547520']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16547090','lexi-content-ref-20547520'])">Ref</a></span>). Effects may include hypoventilation, hypoxia, hypercapnia, respiratory acidosis, and reduced ventilatory responses to hypoxia and hypercapnia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35965031','lexi-content-ref-18456641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35965031','lexi-content-ref-18456641'])">Ref</a></span>). Buprenorphine is a partial mu agonist, resulting in a dose-response ceiling regarding respiratory depression; however, clinically significant respiratory depression may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30915997']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30915997'])">Ref</a></span>). Reversal of buprenorphine-induced respiratory depression may be relatively resistant to naloxone due to its high mu-opioid receptor affinity and slow receptor dissociation kinetics. A higher naloxone bolus dose (ie, 2 to 3 mg IV), followed by a continuous infusion (ie, 4 mg/hour) and/or mechanical ventilation may be required for long-term management and stabilization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30915997','lexi-content-ref-20010421','lexi-content-ref-16809994']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30915997','lexi-content-ref-20010421','lexi-content-ref-16809994'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related at lower doses with a ceiling effect (plateau) at higher doses; stimulation of mu-opioid receptors in the brainstem leads to suppression of the respiratory control network and depression of normal hypoxic and hypercapnic ventilatory responses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30915997','lexi-content-ref-16547090','lexi-content-ref-24629782','lexi-content-ref-16958555','lexi-content-ref-35965031','lexi-content-ref-18456641','lexi-content-ref-35189729']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30915997','lexi-content-ref-16547090','lexi-content-ref-24629782','lexi-content-ref-16958555','lexi-content-ref-35965031','lexi-content-ref-18456641','lexi-content-ref-35189729'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Onset:</i> Rapid; OIRD has been reported within 1 to 2 hours of IV and 2 to 6 hours of sublingual buprenorphine administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28267949','lexi-content-ref-16809994']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28267949','lexi-content-ref-16809994'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:8em;">• Initiation of therapy or dose increase</p>
<p style="text-indent:-2em;margin-left:8em;">• Preexisting respiratory disease (eg, chronic obstructive pulmonary disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29120929','lexi-content-ref-32925317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29120929','lexi-content-ref-32925317'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent benzodiazepines or other CNS depressants, including alcohol</p>
<p style="text-indent:-2em;margin-left:8em;">• Acute overdose</p>
<p style="text-indent:-2em;margin-left:8em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29120929']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29120929'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Cardiac disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29120929']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29120929'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney and/or liver impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29120929']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29120929'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal, opioid-induced or precipitated</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Abruptly stopping or reducing opioid use in patients with physical opioid dependence can result in opioid-induced withdrawal (OIW) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32199668']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32199668'])">Ref</a></span>). Physical symptoms may include nausea, vomiting, diarrhea, abdominal cramps, tachycardia, chills, muscle aches, bone pain, agitation, anxiety, and insomnia. Psychosis has also been described in case reports (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34286498']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34286498'])">Ref</a></span>). Spontaneous withdrawal symptoms due to buprenorphine abstinence are generally milder than those experienced with full opioid agonists (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30701615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30701615'])">Ref</a></span>). Initiation of buprenorphine may cause precipitated opioid withdrawal symptoms (similar to OIW, but faster onset) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22514846','lexi-content-ref-33818748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22514846','lexi-content-ref-33818748'])">Ref</a></span>) in patients currently or recently taking full mu-opioid agonists (prescribed and/or non-prescribed) for a prolonged period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32460142','lexi-content-ref-34173647','lexi-content-ref-17517480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32460142','lexi-content-ref-34173647','lexi-content-ref-17517480'])">Ref</a></span>). Precipitated opioid withdrawal is associated with a decrease in opioid use disorder treatment retention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34954746','lexi-content-ref-20682186']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34954746','lexi-content-ref-20682186'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• OIW: Withdrawal; opioids bind to mu-opioid receptors on neurons in the locus coeruleus (LC) of the brainstem, causing decreased norepinephrine (NE) release. Upon abrupt discontinuation, the absence of opioid stimulation causes LC hyperactivity, excessive NE release, and subsequent autonomic hyperactivity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30701615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30701615'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Precipitated opioid withdrawal: Withdrawal; buprenorphine displaces full agonists at the mu-opioid receptor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22514846','lexi-content-ref-34954746','lexi-content-ref-33818748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22514846','lexi-content-ref-34954746','lexi-content-ref-33818748'])">Ref</a></span>). The sudden shift from full to partial opioid agonism leads to withdrawal symptoms and/or uncontrolled pain.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• OIW: Varied; symptoms typically occur within 2 to 15 days of buprenorphine discontinuation and gradually decrease over the following 4 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30701615','lexi-content-ref-16958555']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30701615','lexi-content-ref-16958555'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Precipitated opioid withdrawal: Rapid; symptoms typically occur within 30 minutes to 2 hours after buprenorphine administration and gradually decrease over the following 6 to 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37151972','lexi-content-ref-33480051','lexi-content-ref-34173647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37151972','lexi-content-ref-33480051','lexi-content-ref-34173647'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors, OIW: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt discontinuation, rapid taper (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32199668']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32199668'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Opioid use disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32199668']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32199668'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors, precipitated opioid withdrawal: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• High level of physical opioid dependence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22514846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22514846'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Recent fentanyl or methadone use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22514846','lexi-content-ref-34173647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22514846','lexi-content-ref-34173647'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent benzodiazepine use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35623179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35623179'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35623179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35623179'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cirrhosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35623179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35623179'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F143121"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported for the sublingual tablet in adults unless otherwise indicated. Also see individual agents.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (11%), constipation (12%)<span class="lexi-table-link-container"> (<a aria-label="Constipation table link" class="lexi-table-link" data-table-id="lexi-content-constipation" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-constipation')">table 1</a>)</span><span class="table-link" style="display:none;">Constipation</span>, nausea (5% to 15%)<span class="lexi-table-link-container"> (<a aria-label="Nausea table link" class="lexi-table-link" data-table-id="lexi-content-nausea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-nausea')">table 2</a>)</span><span class="table-link" style="display:none;">Nausea</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Constipation" frame="border" id="lexi-content-constipation" rules="all">
<caption style="text-align:center;">
<b>Buprenorphine and Naloxone: Adverse Reaction: Constipation</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Buprenorphine and Naloxone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Buprenorphine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Buprenorphine and Naloxone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Buprenorphine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">16 mg buprenorphine/4 mg naloxone per day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Sublingual tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">107</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">103</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">107</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Nausea" frame="border" id="lexi-content-nausea" rules="all">
<caption style="text-align:center;">
<b>Buprenorphine and Naloxone: Adverse Reaction: Nausea</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Buprenorphine and Naloxone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Buprenorphine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Buprenorphine and Naloxone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Buprenorphine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">16 mg buprenorphine/4 mg naloxone per day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Sublingual tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">107</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">103</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">107</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Initial dose of 1.4 mg buprenorphine/0.36 mg naloxone followed by 4.2 mg buprenorphine/1.08 mg naloxone 1.5 hours later</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Sublingual tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">538</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">530</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (7% to 37%), pain (22%), withdrawal syndrome (25%)<span class="lexi-table-link-container"> (<a aria-label="Withdrawal Syndrome table link" class="lexi-table-link" data-table-id="lexi-content-withdrawal-syndrome" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-withdrawal-syndrome')">table 3</a>)</span><span class="table-link" style="display:none;">Withdrawal Syndrome</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Withdrawal Syndrome" frame="border" id="lexi-content-withdrawal-syndrome" rules="all">
<caption style="text-align:center;">
<b>Buprenorphine and Naloxone: Adverse Reaction: Withdrawal Syndrome</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Buprenorphine and Naloxone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Buprenorphine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Buprenorphine and Naloxone)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Buprenorphine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">37%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">16 mg buprenorphine/4 mg naloxone per day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Sublingual tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">107</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">103</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">107</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Vasodilation (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Oral hypoesthesia (sublingual film: &gt;1%), vomiting (5% to 8%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Palpitations (sublingual film)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis (sublingual film), piloerection</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Glossalgia (sublingual film), oral mucosal erythema (sublingual film), stomach discomfort</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, disturbance in attention (sublingual film), insomnia (sublingual film), intoxicated feeling (sublingual film), irritability, restlessness</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (sublingual film), increased lacrimation</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Rhinorrhea</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any route):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dental caries (including tooth fracture, tooth loss) (Suzuki 2012), glossitis, oral bullae, oral mucosa ulcer, stomatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Allodynia (opioid-induced hyperalgesia) (FDA Safety Communication 2023)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm</p></div>
<div class="block coi drugH1Div" id="F143136"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, anaphylactic shock) to buprenorphine, naloxone, or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling (sublingual tablets):</i> Additional contraindications (not in US labeling): Opioid-naive patients; severe respiratory insufficiency (eg, acute or severe bronchial asthma, chronic obstructive airway, status asthmaticus, acute respiratory depression, cor pulmonale); severe hepatic impairment; acute alcohol intoxication or delirium tremens; convulsive or seizure disorders; known or suspected mechanical GI obstruction or diseases/conditions that affect bowel transit (eg, ileus of any type); suspected surgical abdomen (eg, acute appendicitis or pancreatitis); severe CNS depression, increased cerebrospinal or intracranial pressure, or head injury; concurrent use or within 2 weeks of MAO inhibitors.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F143119"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic events: Hepatitis has been reported; hepatic events ranged from transient, asymptomatic transaminase elevations to hepatic failure; in many cases, patients had preexisting hepatic impairment. Monitor liver function tests in patients at increased risk for hepatotoxicity (eg, history of alcohol or IV drug abuse, preexisting hepatic dysfunction) prior to and during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity, including bronchospasm, angioneurotic edema, and anaphylactic shock, have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: May cause severe hypotension, including orthostatic hypotension and syncope; use with caution in patients with hypovolemia, cardiovascular disease (including acute myocardial infarction [MI]), or drugs that may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Monitor for symptoms of hypotension following initiation or dose titration. Use with caution in patients with circulatory shock.</p>
<p style="text-indent:-2em;margin-left:4em;">• QT prolongation: Buprenorphine has been observed to cause QTc prolongation. Avoid using in patients with a personal or family history of long QT syndrome or in patients taking concurrent class IA or III antiarrhythmics or other medications that prolong the QT interval. Use with caution in patients with hypokalemia, hypomagnesemia, or clinically unstable cardiac disease, including unstable heart failure, unstable atrial fibrillation, symptomatic bradycardia, or active MI.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenocortical insufficiency: Use with caution in patients with adrenal insufficiency, including Addison disease. Long-term opioid use may cause secondary hypogonadism, which may lead to mood disorders and osteoporosis (Brennan 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Biliary tract impairment: Use with caution in patients with biliary tract dysfunction, including acute pancreatitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bowel obstruction: Use with caution in patients with a history of ileus or bowel obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression/coma: Use with caution in patients with impaired consciousness or coma because these patients are susceptible to intracranial effects of CO<sub>2</sub> retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Delirium tremens: Use with caution in patients with delirium tremens.</p>
<p style="text-indent:-2em;margin-left:4em;">• Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur. Buprenorphine can produce miosis and changes in the level of consciousness that may interfere with patient evaluation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use is not recommended in patients with moderate hepatic impairment for <i>induction</i> therapy (Suboxone) or in patients with severe hepatic impairment. Use with caution in patients with moderate hepatic impairment for maintenance treatment; due to reduced clearance of naloxone and potential for reduced buprenorphine efficacy, use may not be appropriate.</p>
<p style="text-indent:-2em;margin-left:4em;">• Obesity: Use with caution in patients who are morbidly obese (DeVido 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychosis: Use with caution in patients with toxic psychosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Use with caution and monitor for respiratory depression in patients with significant chronic obstructive pulmonary disease, cor pulmonale, or kyphoscoliosis, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression, particularly when initiating and titrating therapy; critical respiratory depression may occur, even at therapeutic dosages.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure: Use with caution in patients with a history of seizure disorders; may cause or exacerbate preexisting seizures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sleep-related disorders: Use with caution in patients with sleep-related disorders, including sleep apnea, due to increased risk for respiratory and CNS depression. Monitor carefully and titrate dosage cautiously in patients with mild sleep-disordered breathing. Avoid opioids in patients with moderate to severe sleep-disordered breathing (CDC [Dowell 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzodiazepines and other CNS depressants: Concomitant use may result in respiratory depression and sedation, which may be fatal. Consider prescribing naloxone for emergency treatment of opioid overdose in patients taking benzodiazepines or other CNS depressants concomitantly with opioids.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use opioids with caution in older adults; may be more sensitive to adverse effects. Clearance may also be reduced in older adults (with or without renal impairment) resulting in a narrow therapeutic window and increased adverse effects. Monitor closely for adverse effects associated with opioid therapy (eg, respiratory and CNS depression, falls, cognitive impairment, constipation) (CDC [Dowell 2022]). Consider the use of alternative nonopioid analgesics in these patients when possible.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neonates: Neonatal withdrawal syndrome: Prolonged use of opioids during pregnancy can cause neonatal withdrawal syndrome, which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant patient, advise the patient of the risk of neonatal withdrawal syndrome and ensure that appropriate treatment will be available. Signs and symptoms include irritability, hyperactivity and abnormal sleep pattern, high-pitched cry, tremor, vomiting, diarrhea, and failure to gain weight. Onset, duration, and severity depend on the drug used, duration of use, maternal dose, and rate of drug elimination by the newborn.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special handling:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Disposal: Dispose of unused buccal and sublingual films (if they are no longer needed) by removing from foil patch and flushing down the toilet. If multiple films are no longer needed, flush each film individually.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Accidental ingestion: Accidental ingestion in children can result in severe respiratory depression (may be fatal); store buprenorphine-containing medications out of reach of children and dispose of unused medication appropriately.</p>
<p style="text-indent:-2em;margin-left:4em;">• Acute pain: When using buprenorphine for treatment of opioid use disorder, treat acute pain with nonopioid analgesics whenever possible. Dividing buprenorphine daily dose into 3 divided doses may also provide sufficient pain relief (SAMHSA 2021). If treatment with a high-affinity full opioid analgesic is required, monitor closely for respiratory depression because high doses may be necessary to achieve pain relief.</p>
<p style="text-indent:-2em;margin-left:4em;">• Abuse/misuse/substance use disorder: Use exposes patients and other users to the risks of substance use disorder, abuse, and misuse, potentially leading to overdose and death. Assess each patient's risk prior to prescribing; monitor all patients regularly for development of these behaviors or conditions. Use with caution in patients with a history of substance abuse disorder; potential for drug dependency exists. Other factors associated with increased risk for misuse include concomitant depression or other mental health conditions, higher opioid dosages, or taking other CNS depressants (CDC [Dowell 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Buprenorphine/naloxone is not appropriate for pain management; deaths have been reported in opioid-naive patients receiving oral buprenorphine for analgesia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: There is no maximum recommended duration for maintenance treatment of opioid use disorder; patients may require treatment indefinitely. Advise patients of the potential to relapse to illicit drug use following discontinuation of opioid agonist/partial agonist medication-based opioid use disorder treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Naloxone access: Discuss the availability of naloxone with all patients who are prescribed opioid analgesics, as well as their caregivers, and consider prescribing it to patients who are at increased risk of opioid overdose. These include patients who are also taking benzodiazepines or other CNS depressants, have an opioid use disorder (OUD) (current or history of) or substance use disorder, and have higher opioid dosages (≥50 morphine milligram equivalents/day orally) (CDC [Dowell 2022]), or have experienced opioid-induced respiratory depression/opioid overdose. Additionally, health care providers should consider prescribing naloxone to patients prescribed medications to treat OUD; patients at risk of opioid overdose even if they are not taking an opioid analgesic or medication to treat OUD; and patients taking opioids, including methadone or buprenorphine for OUD, if they have household members, including children, or other close contacts at risk for accidental ingestion or opioid overdose. Inform patients and caregivers on options for obtaining naloxone (eg, by prescription, directly from a pharmacist, a community-based program) as permitted by state dispensing and prescribing guidelines. Educate patients and caregivers on how to recognize respiratory depression, proper administration of naloxone, and getting emergency help.</p>
<p style="text-indent:-2em;margin-left:4em;">• Partial opioid agonist and mixed opioid agonist/antagonist overdose: Reversal of partial opioid agonists or mixed opioid agonist/antagonists (eg, buprenorphine, pentazocine) may be incomplete and higher than normal doses and repeated administration of naloxone may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgery: In patients undergoing elective surgery (excluding caesarean section), consider discontinuation of buprenorphine the day before or day of surgery. In patients unable to abruptly discontinue buprenorphine prior to surgery, full opioid agonists may be added to the buprenorphine to maintain proper analgesia. If opioid therapy is required as part of analgesia, patients should be continuously monitored in an anesthesia care setting by persons not involved in in the conduct of the surgical or diagnostic procedure. The decision whether to discontinue buprenorphine prior to elective surgery should be made in consultation with the surgeon and anesthesiologist. If discontinued, buprenorphine can be resumed postoperatively when there is no longer a need for full opioid agonist therapy; in general, presurgery daily doses may be resumed if held for &lt;2 to 3 days (ASAM 2020).</p></div>
<div class="block prod-avail drugH1Div" id="F56788097"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;">Bunavail (buccal film) has been discontinued in the United States for &gt;1 year.</p></div>
<div class="block foc drugH1Div" id="F143130"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Film, Buccal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bunavail: Buprenorphine 6.3 mg and naloxone 1 mg (1 ea [DSC], 30 ea [DSC]); Buprenorphine 2.1 mg and naloxone 0.3 mg (1 ea [DSC], 30 ea [DSC]); Buprenorphine 4.2 mg and naloxone 0.7 mg (1 ea [DSC], 30 ea [DSC]) [contains fd&amp;c blue #1 (brilliant blue), methylparaben, propylparaben, saccharin sodium, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Film, Sublingual: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Suboxone: Buprenorphine 4 mg and naloxone 1 mg (1 ea, 30 ea); Buprenorphine 8 mg and naloxone 2 mg (1 ea, 30 ea); Buprenorphine 12 mg and naloxone 3 mg (1 ea, 30 ea); Buprenorphine 2 mg and naloxone 0.5 mg (1 ea, 30 ea) [contains fd&amp;c yellow #6 (sunset yellow); lime flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Buprenorphine 12 mg and naloxone 3 mg (1 ea, 30 ea); Buprenorphine 2 mg and naloxone 0.5 mg (1 ea, 30 ea); Buprenorphine 4 mg and naloxone 1 mg (1 ea, 30 ea); Buprenorphine 8 mg and naloxone 2 mg (1 ea, 30 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Sublingual, Sublingual: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zubsolv: Buprenorphine 5.7 mg and naloxone 1.4 mg, Buprenorphine 8.6 mg and naloxone 2.1 mg, Buprenorphine 0.7 mg and naloxone 0.18 mg, Buprenorphine 1.4 mg and naloxone 0.36 mg, Buprenorphine 11.4 mg and naloxone 2.9 mg, Buprenorphine 2.9 mg and naloxone 0.71 mg [contains menthol; menthol flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Buprenorphine 2 mg and naloxone 0.5 mg, Buprenorphine 8 mg and naloxone 2 mg</p></div>
<div class="block geq drugH1Div" id="F143116"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F4663306"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Film</b> (Buprenorphine HCl-Naloxone HCl Sublingual)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2-0.5 mg (per each): $4.91 - $5.15</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4-1 mg (per each): $8.79 - $9.23</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8-2 mg (per each): $8.79 - $9.23</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12-3 mg (per each): $17.58 - $18.46</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Film</b> (Suboxone Sublingual)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2-0.5 mg (per each): $6.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4-1 mg (per each): $10.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8-2 mg (per each): $10.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12-3 mg (per each): $21.55</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Sublingual</b> (Buprenorphine HCl-Naloxone HCl Sublingual)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2-0.5 mg (per each): $4.51 - $5.83</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8-2 mg (per each): $7.88 - $10.43</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Sublingual</b> (Zubsolv Sublingual)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.7-0.18 mg (per each): $6.12</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.4-0.36 mg (per each): $6.12</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.9-0.71 mg (per each): $12.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5.7-1.4 mg (per each): $12.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8.6-2.1 mg (per each): $18.37</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">11.4-2.9 mg (per each): $24.50</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52911945"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Film, Sublingual: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Suboxone: Buprenorphine 4 mg and naloxone 1 mg (30 ea); Buprenorphine 8 mg and naloxone 2 mg (30 ea); Buprenorphine 12 mg and naloxone 3 mg (30 ea); Buprenorphine 2 mg and naloxone 0.5 mg (30 ea) [contains fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Sublingual, Sublingual: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Suboxone: Buprenorphine 8 mg and naloxone 2 mg, Buprenorphine 12 mg and naloxone 3 mg, Buprenorphine 16 mg and naloxone 4 mg, Buprenorphine 2 mg and naloxone 0.5 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Buprenorphine 2 mg and naloxone 0.5 mg, Buprenorphine 8 mg and naloxone 2 mg</p></div>
<div class="block csi drugH1Div" id="F143159"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-III</p></div>
<div class="block accres drugH1Div" id="F11217370"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Previously, in order to prescribe buprenorphine for opioid use disorder (OUD) in the United States, clinicians had to apply for a federally required DATA Waiver (X-Waiver). In January 2023, the Consolidated Appropriations Act of 2023 removed this requirement and allowed clinicians with schedule III authority on their Drug Enforcement Administration registration to prescribe buprenorphine for OUD treatment if permitted by applicable state law (<a href="/external-redirect?target_url=https%3A%2F%2Fwww.samhsa.gov%2Fmedications-substance-use-disorders%2Fremoval-data-waiver-requirement&amp;token=IhqDvGshiMFgeaoxwSBa%2FpfG672XB3uk4l4t1pU4LoZwcNeUeGPASmTV3vBw7EwAqIsV4SUDlZAEPs%2BIeDCFOIxvIA4FlMChq%2FOOCXrn59WvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=12919" target="_blank">https://www.samhsa.gov/medications-substance-use-disorders/removal-data-waiver-requirement</a>; <a href="/external-redirect?target_url=https%3A%2F%2Fwww.deadiversion.usdoj.gov%2Fpubs%2Fdocs%2Findex.html&amp;token=yC%2FKZj%2FZo0QTyjIf0bqafcqjZpqX9TrMI0zf%2B%2Fd8YPghll1aghz6pj%2FwmJEojylYEisRy0CdfAnV%2BzZqTZC6Lw%3D%3D&amp;TOPIC_ID=12919" target="_blank">https://www.deadiversion.usdoj.gov/pubs/docs/index.html</a>).</p></div>
<div class="block admp drugH1Div" id="F52612331"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Film:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Although the manufacturer recommends administering the film whole without cutting, chewing, or swallowing, one stability study suggested that Suboxone films split in half have uniform content and maintain stability for up to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31085795']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31085795'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Buccal:</i> Place one film on the inside of one cheek. If a second film is needed, the additional film should be placed on the inside of the opposite cheek. Keep film in place until dissolved; do not move after placement. If a third film is necessary to achieve dose, place it on the inside of one cheek after the first 2 films have dissolved. Once film is completely dissolved, swish a sip of water around the teeth and gums and swallow; wait at least 1 hour after administration to brush teeth. Do not eat or drink until film is completely dissolved. <b>Note: </b>Recommendation to use buccally varies by manufacturer; see manufacturer labeling for details.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Sublingual:</i> Place one film under the tongue close to the base on the left or right side. If a second film is needed, the additional film should be placed under the tongue on the opposite side from the first film. Place the film in a manner to minimize overlapping as much as possible. Keep film in place until dissolved; do not move after placement. If a third film is necessary to achieve the prescribed dose, place it under the tongue on either side after the first 2 films have dissolved. Once film is completely dissolved, swish a sip of water around the teeth and gums and swallow; wait at least 1 hour after administration to brush teeth. Do not eat or drink until film is completely dissolved.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Sublingual tablets:</b> Administer sublingual tablets whole; do not cut, chew, or swallow whole. Immediately after removal from blister pack, tablet should be placed under the tongue until dissolved. May take up to 10 minutes for tablet to completely dissolve (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-SAMSHA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-SAMSHA.2'])">Ref</a></span>). If 2 or more tablets are needed per dose, all may be placed under the tongue at once in different places under the tongue. Alternatively, 1 or 2 tablets may be completely dissolved at a time until required number of tablets has been administered. Patients should follow the same manner of dosing with continued use of the product, to ensure consistency in bioavailability. Once tablet is completely dissolved along oral mucosa, swish a sip of water around the teeth and gums and swallow; wait at least 1 hour after administration to brush teeth. Patients should not eat or drink anything until the tablet(s) are completely dissolved.</p></div>
<div class="block adm drugH1Div" id="F143133"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Film:</p>
<p style="text-indent:-2em;margin-left:4em;">Bunavail: Buccal: Although the manufacturer recommends administering the film whole without cutting, chewing, or swallowing, one stability study (using Suboxone brand) suggested that films split in half have uniform content and maintain stability for up to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31085795']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31085795'])">Ref</a></span>). Immediately before placing the film, moisten inside of cheek with tongue or water. Apply film with a dry finger immediately after removing it from packaging. Place film with the text (BN2, BN4, or BN6) against the inside of the moistened cheek; press and hold the film in place for 5 seconds with finger (film should stay in place after this period). Keep film in place until it dissolves completely. Do not chew, swallow or move film after placement. Once film is completely dissolved, swish a sip of water around the teeth and gums and swallow; wait at least 1 hour after administration to brush teeth. Liquids and food can be consumed after film dissolves. If using more than 1 film simultaneously, the additional film should be placed on the inside of the other cheek; no more than 2 films should be applied to the inside of one cheek at a time.</p>
<p style="text-indent:-2em;margin-left:4em;">Suboxone: May be used buccally or sublingually.</p>
<p style="text-indent:-2em;margin-left:6em;">Buccal: Although the manufacturer recommends administering the film whole without cutting, chewing, or swallowing, one stability study suggested that films split in half have uniform content and maintain stability for up to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31085795']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31085795'])">Ref</a></span>). Place one film on the inside of the right or left cheek. If more than one film is needed, the additional film should be placed on the inside of the opposite cheek. Keep the film on the inside of the cheek until completely dissolved. Once film is completely dissolved, swish a sip of water around the teeth and gums and swallow; wait at least 1 hour after administration to brush teeth. Do not move film after placement. If a third film is necessary, place it on the inside of the right or left cheek after the first 2 films have dissolved.</p>
<p style="text-indent:-2em;margin-left:6em;">Sublingual film: Although the manufacturer recommends administering the film whole without cutting, chewing, or swallowing, one stability study suggested that films split in half have uniform content and maintain stability for up to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31085795']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31085795'])">Ref</a></span>). Place one film under the tongue until the film completely dissolves, close to the base on the left or right side. If more than one film is needed, the additional film should be placed under the tongue on the opposite side from the first film. Place the film in a manner to minimize overlapping as much as possible. Do not move film after placement. If a third film is necessary to achieve the prescribed dose, place it under the tongue on either side after the first 2 films have dissolved. Once film is completely dissolved, swish a sip of water around the teeth and gums and swallow; wait at least 1 hour after administration to brush teeth.</p>
<p style="text-indent:-2em;margin-left:2em;">Sublingual tablet: Immediately after removal from blister pack, tablet should be placed under the tongue until dissolved (can take up to 10 minutes to fully dissolve (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-SAMSHA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-SAMSHA.2'])">Ref</a></span>)). If 2 or more tablets are needed per dose, all may be placed under the tongue at once, or 2 at a time. In patients requiring more than one sublingual tablet, place all tablets in different places under the tongue at the same time. To ensure consistent bioavailability, subsequent doses should always be taken the same way. Patients should not eat or drink anything until the tablet(s) are completely dissolved. If a sequential mode of administration is preferred, patients should follow the same manner of dosing with continued use of the product, to ensure consistency in bioavailability. Do not chew or swallow sublingual tablets. Once tablet(s) are completely dissolved, swish a sip of water around the teeth and gums and swallow; wait at least 1 hour after administration to brush teeth.</p></div>
<div class="block sts drugH1Div" id="F143142"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from freezing and moisture.</p></div>
<div class="block meg drugH1Div" id="F10815685"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:-2em;margin-left:2em;">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Bunavail buccal film:<a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F205637s023s024lbl.pdf%23page%3D33&amp;token=5YzDJZdthZBMk04qZNRrK05zBj9lIKRw0gCdO9SOTIJtK5276Dh%2Byqz%2FvcV%2Fev44YM09bQPuWOW4WysflfA5wsDLoSTdWrWDvSIPxoBmdMhwqhZSPRLjiWs%2Fyt5mPQkg&amp;TOPIC_ID=12919" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/205637s023s024lbl.pdf#page=33</a></p>
<p style="text-indent:-2em;margin-left:4em;">Buprenorphine and naloxone sublingual film for sublingual or buccal administration: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2018%2F022410s033%2C020732s019%2C020733s023lbl.pdf%23page%3D32&amp;token=oY2BzHcUZsetQIHCxLsSGT9iXVJWtThwj73S3nWnxGLfDZ9lARzxXH2UvVQ7XtOeXJi43eh4J9tyFcfvd9onp1DAsykGHFwO7VrsWShED%2FjrPB9Bt7eBdyxpwkn8z1zfEaHHRZCei8z9Eg%2BjbFoMhw%3D%3D&amp;TOPIC_ID=12919" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022410s033,020732s019,020733s023lbl.pdf#page=32</a></p>
<p style="text-indent:-2em;margin-left:4em;">Cassipa sublingual film:<a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F208042s009lbl.pdf%23page%3D30&amp;token=90g79yzKPe0X8k19avZqD1GTkam1E9%2B4C0JqXhkEMkavwoev2CE8Tcl6a8GojIWqNW%2FWd5rQCBeJWrOPtkjlSXfGsRhaAeS0j8I%2B6OAkSOy5GNqs8oDEmdmCo1Qb94qI&amp;TOPIC_ID=12919" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208042s009lbl.pdf#page=30</a></p>
<p style="text-indent:-2em;margin-left:4em;">Suboxone sublingual film:<a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F022410s046s047lbl.pdf%23page%3D35&amp;token=Q%2FT9N9uXoShULc%2Fe%2B2vqU9ifMx1%2Fixc0RWJh%2FMHKODGZU5pZ20TqUbJ6TvJgQyeHqSx6SFn7E7CbmcFEkXTm02PPv%2BJDKASPcg1oschqFaxXKJwDXUagQFLjGuOW3ock&amp;TOPIC_ID=12919" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022410s046s047lbl.pdf#page=35</a></p>
<p style="text-indent:-2em;margin-left:4em;">Suboxone sublingual tablet:<a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F020733s031s032lbl.pdf%23page%3D32&amp;token=UQ0o%2Ff0uMdNcdH%2FC7jgjI0rv0cZ%2BXlc9vRhhBO235wTktzxxFvlIUYn7iRp22kefCt2iwoQpdjcDf%2BlvlkOMUmYXV8EdJWuaR9mI7h%2FCZn6rqvgLbuDLau8Xf6%2FZ6TG5&amp;TOPIC_ID=12919" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020733s031s032lbl.pdf#page=32</a></p>
<p style="text-indent:-2em;margin-left:4em;">Zubsolv sublingual tablet: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F204242s021s023lbl.pdf%23page%3D20&amp;token=PNQ2RiZN6l7yOeofNcBxbqHfhOGiInsirXWDPo9a9SRoPq%2FzCpE9Ens5Gh3rlWDv85VPb8SsGqZdfDlgP0Ma8A4VFwG6BrLskGDD5OWB2vQgLZLDI%2F%2FVHoBg%2B4khzh%2Fl&amp;TOPIC_ID=12919" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/204242s021s023lbl.pdf#page=20</a></p></div>
<div class="block usep drugH1Div" id="F53565742"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Maintenance treatment of opioid use disorder as part of a complete plan that includes counseling and psychosocial support (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F5977973"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Potential for over- or underdosing when switching among various formulations and between strengths of the sublingual films: <b>Not all strengths of sublingual tablets and films are bioequivalent to one another.</b> In addition, systemic exposure between the various strengths of sublingual films may be different; pharmacists should not substitute one or more film strengths for another (eg, dispense three 4 mg films for one 12 mg film, or vice-versa) without physician approval. Any patient switching between sublingual tablet and sublingual film formulation or between one or more strengths of the sublingual films should be monitored for over- or underdosing.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298908"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F143123"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alvimopan: Opioid Agonists may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May enhance the analgesic effect of Opioid Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: Buprenorphine may decrease the serum concentration of Atazanavir. Atazanavir may increase the serum concentration of Buprenorphine.  Management: Buprenorphine is not recommended in patients taking atazanavir without ritonavir. In patients taking atazanavir with ritonavir or cobicistat, monitor for opioid excess if coadministered with buprenorphine and consider buprenorphine dose reductions.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Buprenorphine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Buprenorphine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Buprenorphine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Buprenorphine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daclatasvir: May increase the serum concentration of Buprenorphine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Opioid Agonists may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diuretics: Opioid Agonists may enhance the adverse/toxic effect of Diuretics. Opioid Agonists may diminish the therapeutic effect of Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Opioid Agonists may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Opioid Agonists may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylnaltrexone: May enhance the adverse/toxic effect of Opioid Antagonists. Specifically, the risk for opioid withdrawal may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: Buprenorphine may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: Opioid Antagonists may enhance the adverse/toxic effect of Naldemedine. Specifically, the risk for opioid withdrawal may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nalmefene: May diminish the therapeutic effect of Opioid Agonists. Management: Avoid the concomitant use of oral nalmefene and opioid agonists. Discontinue oral nalmefene 1 week prior to any anticipated use of opioid agonists. If combined, larger doses of opioid agonists will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: Opioid Antagonists may enhance the adverse/toxic effect of Naloxegol. Specifically, the risk for opioid withdrawal may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naltrexone: May diminish the therapeutic effect of Opioid Agonists. Management: Seek therapeutic alternatives to opioids. See full drug interaction monograph for detailed recommendations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: Opioid Agonists (metabolized by CYP3A4) may enhance the serotonergic effect of Nefazodone. This could result in serotonin syndrome. Nefazodone may increase the serum concentration of Opioid Agonists (metabolized by CYP3A4).  Management: If concomitant use of opioid agonists that are metabolized by CYP3A4 and nefazodone is necessary, consider dose reduction of the opioid until stable drug effects are achieved. Monitor for increased opioid effects and serotonin syndrome/serotonin toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: Opioids (Mixed Agonist / Antagonist) may diminish the analgesic effect of Opioid Agonists.  Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioids (Mixed Agonist / Antagonist): May diminish the therapeutic effect of Buprenorphine. This combination may also induce opioid withdrawal.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: Opioid Agonists may diminish the therapeutic effect of Pegvisomant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: May enhance the CNS depressant effect of Buprenorphine. PHENobarbital may decrease the serum concentration of Buprenorphine. Management: Avoid use of buprenorphine and phenobarbital when possible. Monitor for respiratory depression/sedation. Because phenobarbital is also a strong CYP3A4 inducer, monitor for decreased buprenorphine efficacy and withdrawal if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: May enhance the CNS depressant effect of Buprenorphine. Primidone may decrease the serum concentration of Buprenorphine. Management: Avoid use of buprenorphine and primidone when possible. Monitor for respiratory depression/sedation. Because primidone is also a strong CYP3A4 inducer, monitor for decreased buprenorphine efficacy and withdrawal if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Opioid Agonists may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Samidorphan: May diminish the therapeutic effect of Opioid Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): Opioid Agonists (metabolized by CYP3A4) may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Somatostatin Analogs: Opioid Agonists may diminish the analgesic effect of Somatostatin Analogs. Opioid Agonists may enhance the analgesic effect of Somatostatin Analogs. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: May enhance the bradycardic effect of Opioid Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54020738"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Pregnancy testing is recommended prior to initiating therapy for opioid use disorders (ASAM 2020; SAMHSA 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Refer to individual monographs for additional information.</p></div>
<div class="block pri drugH1Div" id="F143138"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Buprenorphine and naloxone can be detected in cord blood following maternal use of sublingual tablets; cord blood concentrations of buprenorphine and naloxone correlate with maternal serum levels (Weigand 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Prolonged use of opioids during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant patient, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure appropriate treatment will be available.</p>
<p style="text-indent:0em;margin-top:2em;">Opioid agonist pharmacotherapy is recommended when treating opioid use disorder in pregnancy (ACOG 2017; ASAM 2020; SAMHSA 2021). Treatment should begin as early in pregnancy as possible (ASAM 2020). Buprenorphine monotherapy is generally preferred when treatment is initiated during pregnancy (ACOG 2017; ASAM 2020; SAMHSA 2021). Based on available data, an increased risk of adverse pregnancy outcomes has not been observed when pregnancy occurs during treatment with buprenorphine/naloxone combination therapy, and continued use may be considered (Ecker [SMFM 2019]; Link 2020; Link 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Refer to individual monographs for additional information.</p></div>
<div class="block mopp drugH1Div" id="F53565741"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">BP (monitor for hypotension during initiation and titration); LFTs (prior to initiation and during therapy); pregnancy test in patients who can become pregnant (prior to initiation); hepatitis and HIV tests (prior to initiation, particularly for patients with opioid use disorder) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-SAMSHA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-SAMSHA.2'])">Ref</a></span>); respiratory and mental status, CNS depression; signs of dependence, abuse, or misuse; symptoms of withdrawal; patients with biliary tract disease for worsening symptoms; signs or symptoms of hypogonadism or hypoadrenalism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23414717']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23414717'])">Ref</a></span>); signs and symptoms of toxicity or overdose (especially in patients with hepatic impairment). Dental changes (cavities, tooth erosion/decay, loss of fillings, tooth loss).</p></div>
<div class="block pha drugH1Div" id="F143118"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: Buprenorphine exerts its analgesic effect via high affinity binding to mu opiate receptors in the CNS; displays partial mu agonist and weak kappa antagonist activity</p>
<p style="text-indent:-2em;margin-left:2em;">Naloxone: Pure opioid antagonist that competes and displaces opioids at opioid receptor sites</p></div>
<div class="block phk drugH1Div" id="F143135"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Also see individual agents.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Absorption widely is variable among patients following sublingual and buccal use, but variability within each individual patient is low.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability:</p>
<p style="text-indent:-2em;margin-left:4em;">Buccal film: The exposure of one buprenorphine 4.2 mg/naloxone 0.7 mg buccal film is equivalent to one buprenorphine 8 mg/naloxone 2 mg sublingual tablet. The naloxone exposure from buccal film was 33% less than buprenorphine/naloxone sublingual tablets. The coadministration of liquids reduced the systemic exposure up to 59% for buprenorphine and up to 76% for naloxone, depending on the pH of the liquid.</p>
<p style="text-indent:-2em;margin-left:4em;">Sublingual: Although pharmacokinetics were similar between the sublingual formulations, bioequivalence is variable.</p>
<p style="text-indent:-2em;margin-left:6em;">Sublingual film: Potential for greater bioavailability with certain strengths of the sublingual film compared to the same strength of the sublingual tablet. In addition, the sizes and compositions among the sublingual film strengths are different which may result in different systemic exposures.</p>
<p style="text-indent:-2em;margin-left:6em;">Sublingual tablet: Zubsolv has different bioavailability when compared to other buprenorphine/naloxone sublingual tablets. One Zubsolv buprenorphine 5.7 mg/naloxone 1.4 mg sublingual tablet provides equivalent buprenorphine exposure and 12% lower naloxone exposure compared to one buprenorphine 8 mg/naloxone 2 mg sublingual tablet.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Suboxone: Buprenorphine 24 to 42 hours; Naloxone 2 to 12 hours; Bunavail: Buprenorphine 16.4 to 27.5 hours; Naloxone 1.9 to 2.4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Buprenorphine: ~96%, primarily to alpha and beta globulin; Naloxone: ~45%, primarily to albumin.</p></div>
<div class="block phksp drugH1Div" id="F51154181"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Because both drugs are extensively metabolized, the plasma levels will be expected to be higher and the half-life values have been shown to be longer in patients with moderate and severe hepatic impairment; the significance of the effects are greater for naloxone compared to buprenorphine and for patients with severe hepatic impairment compared to patients with moderate hepatic impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038544"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Suboxone</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Bupensan duo | Suboxone</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Libroxar | Zubsolv</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Suboxone</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Bupensanduo | Libroxar | Zubsolv</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Bowielone | Bunalict | Bupensanduo | Suboxone | Zubsolv</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Bupensanduo | Zubsolv</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Buprenorfina/Naloxona Aurovitas | Buprenorphine/naloxone tillomed | Suboxone | Zubsolv</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Bunalict | Buprenorphine/Naloxone G.L. Pharma | Buprenorphine/Naloxone Mylan | Suboxone | Zubsolv</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Buprenorphine/naloxone arrow | Suboxone</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Buprenorphine/naloxone | Buprenorphine/naloxone ethypharm | Suboxone | Zubsolv</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Suboxone</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Buprenorfin/Nalokson Mylan | Suboxone</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Bulnexo | Suboxone | Suboxone Reckitt</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Suboxone | Zubsolv</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Addnok n | Qudict</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Bunamol | Buprenorfina e naloxone ethypharm | Buprenorfina e Naloxone Mylan Pharma | Suboxone</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Addnok n</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Suboxone</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Bupensanduo | Zubsolv</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Libroxar | Suboxone</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Bupensanduo | Suboxone | Zubsolv</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Bunalict | Buprenorfine/naloxon aurobindo | Buprenorfine/Naloxon Mylan | Libroxar | Suboxone | Zubsolv</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Bunalict | Suboxone | Zubsolv</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Buprenorphine naloxone bnm | Temgesic-nx</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Suboxone</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Buprenorphine and naloxone | Buprenorphine hcl and naloxone hcl | Buprenorphine/naloxone | Suboxone | Zubsolv</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Buprenorfin+naloxona</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Suboxone</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Zubsolv</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Bupraxon</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Bunalict | Buprenorphine/Naloxone G.L. Pharma | Buprenorphine/Naloxone Mylan | Suboxone | Zubsolv</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Bulnexo | Suboxone | Zubsolv</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Bupensanduo</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Suboxone</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Desud Plus | Suboxone</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Suboxone</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21718572">
<a name="21718572"></a>Ahmedzai SH, Boland J. Constipation in people prescribed opioids.<i> BMJ Clin Evid</i>. 2010;2010:2407.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/21718572/pubmed" id="21718572" target="_blank">21718572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30915997">
<a name="30915997"></a>Algera MH, Kamp J, van der Schrier R, et al. Opioid-induced respiratory depression in humans: a review of pharmacokinetic-pharmacodynamic modelling of reversal. <i>Br J Anaesth</i>. 2019;122(6):e168-e179. doi:10.1016/j.bja.2018.12.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/30915997/pubmed" id="30915997" target="_blank">30915997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28742676">
<a name="28742676"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee opinion no. 711: opioid use and opioid use disorder in pregnancy. <i>Obstet Gynecol</i>. 2017;130(2):e81-e94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/28742676/pubmed" id="28742676" target="_blank">28742676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32511106">
<a name="32511106"></a>American Society of Addiction Medicine (ASAM). The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. <i>J Addict Med</i>. 2020;14(2S)(suppl 1):1‐91. doi:10.1097/ADM.0000000000000633<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/32511106/pubmed" id="32511106" target="_blank">32511106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21937837">
<a name="21937837"></a>Aurilio C, Ceccarelli I, Pota V, et al. Endocrine and behavioural effects of transdermal buprenorphine in pain-suffering women of different reproductive ages. <i>Endocr J</i>. 2011;58(12):1071-1078.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/21937837/pubmed" id="21937837" target="_blank">21937837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32460142">
<a name="32460142"></a>Bhatia G, Sarkar S. Sublingual buprenorphine-naloxone precipitated withdrawal - a case report with review of literature and clinical considerations. <i>Asian J Psychiatr</i>. 2020;53:102121. doi:10.1016/j.ajp.2020.102121<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/32460142/pubmed" id="32460142" target="_blank">32460142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15483091">
<a name="15483091"></a>Bliesener N, Albrecht S, Schwager A, Weckbecker K, Lichtermann D, Klingmüller D. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. <i>J Clin Endocrinol Metab</i>. 2005;90(1):203-206.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/15483091/pubmed" id="15483091" target="_blank">15483091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32199668">
<a name="32199668"></a>Bluthenthal RN, Simpson K, Ceasar RC, Zhao J, Wenger L, Kral AH. Opioid withdrawal symptoms, frequency, and pain characteristics as correlates of health risk among people who inject drugs. <i>Drug Alcohol Depend</i>. 2020;211:107932. doi:10.1016/j.drugalcdep.2020.107932<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/32199668/pubmed" id="32199668" target="_blank">32199668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22747535">
<a name="22747535"></a>Boom M, Niesters M, Sarton E, Aarts L, Smith TW, Dahan A. non-analgesic effects of opioids: opioid-induced respiratory depression. <i>Curr Pharm Des</i>. 2012;18(37):5994-6004. doi:10.2174/138161212803582469<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/22747535/pubmed" id="22747535" target="_blank">22747535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23414717">
<a name="23414717"></a>Brennan MJ. The effect of opioid therapy on endocrine function. <i>Am J Med</i>. 2013;126(3) (Suppl 1):S12-S18. doi: 10.1016/j.amjmed.2012.12.001.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/23414717/pubmed" id="23414717" target="_blank">23414717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BioDelivery.1">
<a name="BioDelivery.1"></a>Bunavail (buprenorphine/naloxone) [prescribing information]. Raleigh, NC: BioDelivery Sciences International Inc; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alvogen.1">
<a name="Alvogen.1"></a>Buprenorphine and naloxone sublingual film [prescribing information]. Pine Brook, NJ: Alvogen Inc; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-SunPharm.1">
<a name="SunPharm.1"></a>Buprenorphine and naloxone sublingual tablets [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-SunPharm.2">
<a name="SunPharm.2"></a>Buprenorphine and naloxone sublingual tablets [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries Inc; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lannett.1">
<a name="Lannett.1"></a>Buprenorphine and naloxone sublingual tablets [prescribing information]. Philadelphia, PA: Lannett Company Inc; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-SpecGx.1">
<a name="SpecGx.1"></a>Buprenorphine and naloxone sublingual tablets [prescribing information]. Webster Groves, MO: SpecGx LLC; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9559604">
<a name="9559604"></a>Cammarano WB, Pittet JF, Weitz S, Schlobohm RM, Marks JD. Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. <i>Crit Care Med</i>. 1998;26(4):676-684. doi:10.1097/00003246-199804000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/9559604/pubmed" id="9559604" target="_blank">9559604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Teva.1">
<a name="Teva.1"></a>Cassipa (buprenorphine/naloxone) sublingual film [prescribing information]. West Caldwell, NJ: Lohmann Therapy Systems Corp (LTS); received March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22514846">
<a name="22514846"></a>Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2004. Report No.:(SMA) 04-3939.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/22514846/pubmed" id="22514846" target="_blank">22514846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34954746">
<a name="34954746"></a>Cohen SM, Weimer MB, Levander XA, Peckham AM, Tetrault JM, Morford KL. Low dose initiation of buprenorphine: a narrative review and practical approach. <i>J Addict Med</i>. 2022;16(4):399-406. doi:10.1097/ADM.0000000000000945<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/34954746/pubmed" id="34954746" target="_blank">34954746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30340754">
<a name="30340754"></a>Crockett SD, Greer KB, Heidelbaugh JJ, Falck-Ytter Y, Hanson BJ, Sultan S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on the medical management of opioid-induced constipation. <i>Gastroenterology</i>. 2019;156(1):218-226. doi:10.1053/j.gastro.2018.07.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/30340754/pubmed" id="30340754" target="_blank">30340754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2721544">
<a name="2721544"></a>Cuer JC, Dapoigny M, Ajmi S, Larpent JL, Lunaud B, Ferrier C, Bommelaer G. Effects of buprenorphine on motor activity of the sphincter of Oddi in man. <i>Eur J Clin Pharmaco</i>l. 1989;36(2):203-204. doi:10.1007/BF00609196<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/2721544/pubmed" id="2721544" target="_blank">2721544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20010421">
<a name="20010421"></a>Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. <i>Anesthesiology</i>. 2010;112(1):226-238. doi:10.1097/ALN.0b013e3181c38c25<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/20010421/pubmed" id="20010421" target="_blank">20010421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16547090">
<a name="16547090"></a>Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. <i>Br J Anaesth</i>. 2006;96(5):627-632. doi:10.1093/bja/ael051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/16547090/pubmed" id="16547090" target="_blank">16547090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16010532">
<a name="16010532"></a>Davis MP. Buprenorphine in cancer pain. <i>Support Care Cancer</i>. 2005;13(11):878-887. doi:10.1007/s00520-005-0849-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/16010532/pubmed" id="16010532" target="_blank">16010532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33818748">
<a name="33818748"></a>De Aquino JP, Parida S, Sofuoglu M. The pharmacology of buprenorphine microinduction for opioid use disorder. <i>Clin Drug Investig</i>. 2021;41(5):425-436. doi:10.1007/s40261-021-01032-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/33818748/pubmed" id="33818748" target="_blank">33818748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26312963">
<a name="26312963"></a>DeVido J, Connery H, Hill KP. Sleep-disordered breathing in patients with opioid use disorders in long-term maintenance on buprenorphine-naloxone: a case series. <i>J Opioid Manag</i>. 2015;11(4):363-366.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/26312963/pubmed" id="26312963" target="_blank">26312963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36327391">
<a name="36327391"></a>Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain - United States, 2022. <i>MMWR Recomm Rep</i>. 2022;71(3):1-95. doi:10.15585/mmwr.rr7103a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/36327391/pubmed" id="36327391" target="_blank">36327391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37151972">
<a name="37151972"></a>Dunn KE, Bird HE, Bergeria CL, Ware OD, Strain EC, Huhn AS. Operational definition of precipitated opioid withdrawal. <i>Front Psychiatry</i>. 2023;14:1141980. doi:10.3389/fpsyt.2023.1141980<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/37151972/pubmed" id="37151972" target="_blank">37151972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30928567">
<a name="30928567"></a>Ecker J, Abuhamad A, Hill W, et al. Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine. <i>Am J Obstet Gynecol.</i> 2019;221(1):B5-B28. doi:10.1016/j.ajog.2019.03.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/30928567/pubmed" id="30928567" target="_blank">30928567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36511932">
<a name="36511932"></a>Etminan M, Rezaeianzadeh R, Kezouh A, Aminzadeh K. Association between sublingual buprenorphine-naloxone exposure and dental disease. <i>JAMA</i>. 2022;328(22):2269-2271. doi:10.1001/jama.2022.17485<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/36511932/pubmed" id="36511932" target="_blank">36511932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30788113">
<a name="30788113"></a>Farmer AD, Drewes AM, Chiarioni G, et al. Pathophysiology and management of opioid-induced constipation: European expert consensus statement. <i>United European Gastroenterol J</i>. 2019;7(1):7-20. doi:10.1177/2050640618818305<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/30788113/pubmed" id="30788113" target="_blank">30788113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>FDA Drug Safety Communication. FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain. January 12, 2022. Available at <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-dental-problems-buprenorphine-medicines-dissolved-mouth-treat-opioid-use-disorder" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-dental-problems-buprenorphine-medicines-dissolved-mouth-treat-opioid-use-disorder</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/FDA.1/pubmed" id="FDA.1" target="_blank">FDA.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28646524">
<a name="28646524"></a>Fox LM, Hoffman RS, Vlahov D, Manini AF. Risk factors for severe respiratory depression from prescription opioid overdose. <i>Addiction</i>. 2018;113(1):59-66. doi:10.1111/add.13925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/28646524/pubmed" id="28646524" target="_blank">28646524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20547520">
<a name="20547520"></a>Gallagher R. Killing the symptom without killing the patient. <i>Can Fam Physician</i>. 2010;56(6):544-546, e210-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/20547520/pubmed" id="20547520" target="_blank">20547520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29120929">
<a name="29120929"></a>Gupta K, Prasad A, Nagappa M, Wong J, Abrahamyan L, Chung FF. Risk factors for opioid-induced respiratory depression and failure to rescue: a review. <i>Curr Opin Anaesthesiol</i>. 2018;31(1):110-119. doi:10.1097/ACO.0000000000000541<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/29120929/pubmed" id="29120929" target="_blank">29120929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29273520">
<a name="29273520"></a>Imam MZ, Kuo A, Ghassabian S, Smith MT. Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression. <i>Neuropharmacology</i>. 2018;131:238-255. doi:10.1016/j.neuropharm.2017.12.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/29273520/pubmed" id="29273520" target="_blank">29273520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32925318">
<a name="32925318"></a>Khanna AK, Bergese SD, Jungquist CR, et al. Prediction of opioid-induced respiratory depression on inpatient wards using continuous capnography and oximetry: an international prospective, observational trial. <i>Anesth Analg</i>. 2020;131(4):1012-1024. doi:10.1213/ANE.0000000000004788<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/32925318/pubmed" id="32925318" target="_blank">32925318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26672499">
<a name="26672499"></a>Khanna IK, Pillarisetti S. Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain. <i>J Pain Res</i>. 2015;8:859-70. doi:10.2147/JPR.S85951<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/26672499/pubmed" id="26672499" target="_blank">26672499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30701615">
<a name="30701615"></a>Kosten TR, Baxter LE. Review article: effective management of opioid withdrawal symptoms: a gateway to opioid dependence treatment. <i>Am J Addict</i>. 2019;28(2):55-62. doi:10.1111/ajad.12862<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/30701615/pubmed" id="30701615" target="_blank">30701615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24629782">
<a name="24629782"></a>Lee SC, Klein-Schwartz W, Doyon S, Welsh C. Comparison of toxicity associated with nonmedical use of benzodiazepines with buprenorphine or methadone. <i>Drug Alcohol Depend</i>. 2014;138:118-123. doi:10.1016/j.drugalcdep.2014.02.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/24629782/pubmed" id="24629782" target="_blank">24629782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33831585">
<a name="33831585"></a>Link HM, Jones HE, Miller LA, Kaltenbach K, Seligman NS. Buprenorphine-naloxone use in pregnancy: a subgroup analysis of medication to treat opioid use disorder. <i>Am J Obstet Gynecol MFM.</i> 2021;3(5):100369. doi:10.1016/j.ajogmf.2021.100369<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/33831585/pubmed" id="33831585" target="_blank">33831585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33345863">
<a name="33345863"></a>Link HM, Jones H, Miller L, Kaltenbach K, Seligman N. Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis.<i> Am J Obstet Gynecol MFM.</i> 2020;2(3):100179. doi:10.1016/j.ajogmf.2020.100179<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/33345863/pubmed" id="33345863" target="_blank">33345863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32422060">
<a name="32422060"></a>Loomis E, Bajwa J, Kaizuka S. Buprenorphine-naloxone as a novel treatment of narcotic bowel syndrome: a case report. <i>Ann Intern Med</i>. 2020;173(2):164-166. doi:10.7326/L19-0798<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/32422060/pubmed" id="32422060" target="_blank">32422060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34286498">
<a name="34286498"></a>Lozano-López MT, Gamonal-Limcaoco S, Casado-Espada N, et al. Psychosis after buprenorphine, heroin, methadone, morphine, oxycodone, and tramadol withdrawal: a systematic review. <i>Eur Rev Med Pharmacol Sci</i>. 2021;25(13):4554-4562. doi:10.26355/eurrev_202107_26248<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/34286498/pubmed" id="34286498" target="_blank">34286498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15664721">
<a name="15664721"></a>Marsch LA, Bickel WK, Badger GJ, Jacobs EA. Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing. <i>Drug Alcohol Depend</i>. 2005;77(2):195-204. doi:10.1016/j.drugalcdep.2004.08.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/15664721/pubmed" id="15664721" target="_blank">15664721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15153834">
<a name="15153834"></a>McMillan SC. Assessing and managing opiate-induced constipation in adults with cancer. <i>Cancer Control</i>. 2004;11(3 Suppl):3-9. doi:10.1177/10732748040110S302<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/15153834/pubmed" id="15153834" target="_blank">15153834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16958555">
<a name="16958555"></a>Mégarbane B, Hreiche R, Pirnay S, Marie N, Baud FJ. Does high-dose buprenorphine cause respiratory depression?: possible mechanisms and therapeutic consequences. <i>Toxicol Rev</i>. 2006;25(2):79-85. doi:10.2165/00139709-200625020-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/16958555/pubmed" id="16958555" target="_blank">16958555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35965031">
<a name="35965031"></a>Montandon G. The pathophysiology of opioid-induced respiratory depression. <i>Handb Clin Neurol</i>. 2022;188:339-355. doi:10.1016/B978-0-323-91534-2.00003-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/35965031/pubmed" id="35965031" target="_blank">35965031</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28034973">
<a name="28034973"></a>Müller-Lissner S, Bassotti G, Coffin B, et al. Opioid-induced constipation and bowel dysfunction: a clinical guideline. <i>Pain Med</i>. 2017;18(10):1837-1863. doi:10.1093/pm/pnw255<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/28034973/pubmed" id="28034973" target="_blank">28034973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26136838">
<a name="26136838"></a>Nelson AD, Camilleri M. Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities. <i>Therap Adv Gastroenterol</i>. 2015;8(4):206-220. doi:10.1177/1756283X15578608<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/26136838/pubmed" id="26136838" target="_blank">26136838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33480051">
<a name="33480051"></a>Oakley B, Wilson H, Hayes V, Lintzeris N. Managing opioid withdrawal precipitated by buprenorphine with buprenorphine. <i>Drug Alcohol Rev</i>. 2021;40(4):567-571. doi:10.1111/dar.13228<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/33480051/pubmed" id="33480051" target="_blank">33480051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11755892">
<a name="11755892"></a>Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. <i>Am J Surg</i>. 2001;182(5A Suppl):11S-18S. doi:10.1016/s0002-9610(01)00782-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/11755892/pubmed" id="11755892" target="_blank">11755892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18456641">
<a name="18456641"></a>Pattinson KT. Opioids and the control of respiration. <i>Br J Anaesth</i>. 2008;100(6):747-758. doi:10.1093/bja/aen094<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/18456641/pubmed" id="18456641" target="_blank">18456641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35189729">
<a name="35189729"></a>Pattullo GG. Clinical implications of opioid-induced ventilatory impairment. <i>Anaesth Intensive Care</i>. 2022;50(1-2):52-67. doi:10.1177/0310057X211070292<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/35189729/pubmed" id="35189729" target="_blank">35189729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32925317">
<a name="32925317"></a>Prielipp RC, Fulesdi B, Brull SJ. Postoperative opioid-induced respiratory depression: 3 steps forward. <i>Anesth Analg</i>. 2020;131(4):1007-1011. doi:10.1213/ANE.0000000000005098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/32925317/pubmed" id="32925317" target="_blank">32925317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34173647">
<a name="34173647"></a>Quattlebaum THN, Kiyokawa M, Murata KA. A case of buprenorphine-precipitated withdrawal managed with high-dose buprenorphine. <i>Fam Pract</i>. 2022;39(2):292-294. doi:10.1093/fampra/cmab073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/34173647/pubmed" id="34173647" target="_blank">34173647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31085795">
<a name="31085795"></a>Reindel KL, DeAngelis MJ, Ferrara AS, et al. An exploratory study of Suboxone (buprenorphine/naloxone) film splitting: cutting methods, content uniformity, and stability. <i>Int J Pharm Compd</i>. 2019;23(3):258-263.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/31085795/pubmed" id="31085795" target="_blank">31085795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28267949">
<a name="28267949"></a>Richards S, Torre L, Lawther B. Buprenorphine-related complications in elderly hospitalised patients: a case series. <i>Anaesth Intensive Care</i>. 2017;45(2):256-261. doi:10.1177/0310057X1704500217<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/28267949/pubmed" id="28267949" target="_blank">28267949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17517480">
<a name="17517480"></a>Rosado J, Walsh SL, Bigelow GE, Strain EC. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. <i>Drug Alcohol Depend</i>. 2007;90(2-3):261-269. doi:10.1016/j.drugalcdep.2007.04.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/17517480/pubmed" id="17517480" target="_blank">17517480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30778756">
<a name="30778756"></a>Rossi M, Casale G, Badiali D, et al. Opioid-induced bowel dysfunction: suggestions from a multidisciplinary expert Board. <i>Support Care Cancer</i>. 2019;27(11):4083-4090. doi:10.1007/s00520-019-04688-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/30778756/pubmed" id="30778756" target="_blank">30778756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22541841">
<a name="22541841"></a>Smith K, Hopp M, Mundin G, et al, "Low Absolute Bioavailability of Oral Naloxone in Healthy Subjects," <i>Int J Clin Pharmacol Ther</i>, 2012, 50(5):360-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/22541841/pubmed" id="22541841" target="_blank">22541841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35623179">
<a name="35623179"></a>Spadaro A, Long B, Koyfman A, Perrone J. Buprenorphine precipitated opioid withdrawal: Prevention and management in the ED setting. <i>Am J Emerg Med</i>. 2022;58:22-26. doi:10.1016/j.ajem.2022.05.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/35623179/pubmed" id="35623179" target="_blank">35623179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Indivior.1">
<a name="Indivior.1"></a>Suboxone (buprenorphine/naloxone) sublingual film [prescribing information]. North Chesterfield, VA: Indivior Inc; received March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pharma.1">
<a name="Pharma.1"></a>Suboxone (buprenorphine/naloxone) sublingual film and sublingual tablet [product monograph]. Toronto, Ontario, Canada: Pharma Importing Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-SAMSHA.2">
<a name="SAMSHA.2"></a>Substance Abuse and Mental Health Services Administration (SAMHSA). Medications for opioid use disorder. Treatment Improvement Protocol (TIP) Series 63 Publication No. PEP21-02-01-002. <a href="https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP21-02-01-002.pdf" target="_blank">https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP21-02-01-002.pdf</a>. Published 2021. Accessed September 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24511440">
<a name="24511440"></a>Suzuki J, Mittal L, Woo SB. Sublingual buprenorphine and dental problems: a case series. <i>Prim Care Companion CNS Disord</i>. 2013;15(5):PCC.13l01533. doi:10.4088/PCC.13l01533<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/24511440/pubmed" id="24511440" target="_blank">24511440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22882403">
<a name="22882403"></a>Suzuki J, Park EM. Buprenorphine/naloxone and dental caries: a case report. <i>Am J Addict</i>. 2012;21(5):494-495. doi:10.1111/j.1521-0391.2012.00254.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/22882403/pubmed" id="22882403" target="_blank">22882403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17087429">
<a name="17087429"></a>Swegle JM, Logemann C. Management of common opioid-induced adverse effects. <i>Am Fam Physician</i>. 2006;74(8):1347-1354.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/17087429/pubmed" id="17087429" target="_blank">17087429</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Food and Drug Administration (FDA). FDA drug safety communication: FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use</a>. Published April 13, 2023. Accessed April 17, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16809994">
<a name="16809994"></a>van Dorp E, Yassen A, Sarton E, et al. Naloxone reversal of buprenorphine-induced respiratory depression. <i>Anesthesiology</i>. 2006;105(1):51-57. doi:10.1097/00000542-200607000-00012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/16809994/pubmed" id="16809994" target="_blank">16809994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31589332">
<a name="31589332"></a>Varga AG, Reid BT, Kieffer BL, Levitt ES. Differential impact of two critical respiratory centres in opioid-induced respiratory depression in awake mice. <i>J Physiol</i>. 2020;598(1):189-205. doi:10.1113/JP278612<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/31589332/pubmed" id="31589332" target="_blank">31589332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30855724">
<a name="30855724"></a>Velázquez Rivera I, Velázquez Clavarana L, García Velasco P, Melero Ramos C. Opioid-induced constipation in chronic pain: experience with 180 patients. <i>J Opioid Manag</i>. 2019;15(1):69-76. doi:10.5055/jom.2019.0487<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/30855724/pubmed" id="30855724" target="_blank">30855724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32448458">
<a name="32448458"></a>Viswanath A, Barreveld AM, Fortino M. Assessment and management of the high-risk dental patient with active substance use disorder. <i>Dent Clin North Am</i>. 2020;64(3):547-558. doi:10.1016/j.cden.2020.02.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/32448458/pubmed" id="32448458" target="_blank">32448458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28866754">
<a name="28866754"></a>Wang PP, Huang E, Feng X, et al. Opioid-associated iatrogenic withdrawal in critically ill adult patients: a multicenter prospective observational study. <i>Ann Intensive Care</i>. 2017;7(1):88. doi:10.1186/s13613-017-0310-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/28866754/pubmed" id="28866754" target="_blank">28866754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27366109">
<a name="27366109"></a>Webster LR, Camilleri M, Finn A. Opioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individuals. <i>Subst Abuse Rehabil</i>. 2016;7:81-86. doi:10.2147/SAR.S100998<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/27366109/pubmed" id="27366109" target="_blank">27366109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20682186">
<a name="20682186"></a>Whitley SD, Sohler NL, Kunins HV, et al. Factors associated with complicated buprenorphine inductions. <i>J Subst Abuse Treat</i>. 2010;39(1):51-57. doi:10.1016/j.jsat.2010.04.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/20682186/pubmed" id="20682186" target="_blank">20682186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27896019">
<a name="27896019"></a>Wiegand SL, Swortwood MJ, Huestis MA, Thorp J, Jones HE, Vora NL. Naloxone and metabolites quantification in cord blood of prenatally exposed newborns and correlations with maternal concentrations. <i>AJP Rep</i>. 2016;6(4):e385-e390.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/27896019/pubmed" id="27896019" target="_blank">27896019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32041585">
<a name="32041585"></a>Yazdanian M, Armoon B, Noroozi A, et al. Dental caries and periodontal disease among people who use drugs: a systematic review and meta-analysis. <i>BMC Oral Health</i>. 2020;20(1):44. doi:10.1186/s12903-020-1010-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/32041585/pubmed" id="32041585" target="_blank">32041585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29671504">
<a name="29671504"></a>Zoorob R, Kowalchuk A, Mejia de Grubb M. Buprenorphine therapy for opioid use disorder. <i>Am Fam Physician</i>. 2018;97(5):313-320.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/buprenorphine-and-naloxone-pediatric-drug-information/abstract-text/29671504/pubmed" id="29671504" target="_blank">29671504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Orexo.1">
<a name="Orexo.1"></a>Zubsolv (buprenorphine/naloxone) [prescribing information]. Morristown, NJ: Orexo US Inc; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Orexo.2">
<a name="Orexo.2"></a>Zubsolv (buprenorphine/naloxone) [prescribing information]. Morristown, NJ: Orexo US Inc; March 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 12919 Version 493.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
